Cimidahurinine is primarily investigated for its potential antimalarial properties. It has shown activity against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. The compound belongs to a class of natural products that interfere with parasite development in red blood cells, making it a candidate for antiparasitic drug development. Research is ongoing to evaluate its efficacy, safety, and mechanism of action in preclinical models. Its complex alkaloid structure also makes it a subject of interest in synthetic organic chemistry for the development of novel derivatives with improved pharmacological profiles.